MicroRNA-10b and minichromosome maintenance complex component 5 gene as prognostic biomarkers in breast cancer

Eissa, Sanaa; Matboli, Marwa; Shehata, Hanan H.; Essawy, Nada

doi:10.1007/s13277-015-3090-2

Cited by 32 publications

(24 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…miR-10b overexpression was associated with poor prognosis in breast cancer37 and gliomas 38. In colon cancer, miR-10b showed increasing expression in higher stage disease 39.…”

Section: Discussionmentioning

confidence: 97%

miR-10b is a prognostic marker in clear cell renal cell carcinoma

et al. 2017

View full text Add to dashboard Cite

show abstract

“…miR-10b overexpression was associated with poor prognosis in breast cancer37 and gliomas 38. In colon cancer, miR-10b showed increasing expression in higher stage disease 39.…”

Section: Discussionmentioning

confidence: 97%

miR-10b is a prognostic marker in clear cell renal cell carcinoma

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Zhao et al [26] demonstrated that miR-221 may be a predictive biomarker for BC. In the research of Eissa et al [27], patients with BC positive for miR-10b had shorter relapse-free survival rates, and miR-10b was an independent prognostic factor of BC. MiR-451 influenced the drug resistances and miR-129-5p regulated radiosensitivity via accelerating the apoptosis of breast cancer cells [28,29].…”

Section: Discussionmentioning

confidence: 99%

Clinical Value of miR-101-3p and Biological Analysis of its Prospective Targets in Breast Cancer: A Study Based on The Cancer Genome Atlas (TCGA) and Bioinformatics

Xiong

Huang

et al. 2017

Med Sci Monit

View full text Add to dashboard Cite

BackgroundMiR-101-3p can promote apoptosis and inhibit proliferation, invasion, and metastasis in breast cancer (BC) cells. However, its mechanisms in BC are not fully understood. Therefore, a comprehensive analysis of the target genes, pathways, and networks of miR-101-3p in BC is necessary.Material/MethodsThe miR-101 profiles for 781 patients with BC from The Cancer Genome Atlas (TCGA) were analyzed. Gene expression profiling of GSE31397 with miR-101-3p transfected MCF-7 cells and scramble control cells was downloaded from Gene Expression Omnibus (GEO), and the differentially expressed genes (DEGs) were identified. The potential genes targeted by miR-101-3p were also predicted. Gene Ontology (GO) and pathway and network analyses were constructed for the DEGs and predicted genes.ResultsIn the TCGA data, a low level of miR-101-2 expression might represent a diagnostic (AUC: 0.63) marker, and the miR-101-1 was a prognostic (HR=1.79) marker. MiR-101-1 was linked to the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), and miR-101-2 was associated with the tumor (T), lymph node (N), and metastasis (M) stages of BC. Moreover, 427 genes were selected from the 921 DEGs in GEO and the 7924 potential target genes from the prediction databases. These genes were related to transcription, metabolism, biosynthesis, and proliferation. The results were also significantly enriched in the VEGF, mTOR, focal adhesion, Wnt, and chemokine signaling pathways.ConclusionsMiR-101-1 and miR-101-2 may be prospective biomarkers for the prognosis and diagnosis of BC, respectively, and are associated with diverse clinical parameters. The target genes of miR-101-3p regulate the development and progression of BC. These results provide insight into the pathogenic mechanism and potential therapies for BC.

show abstract

“…The association between the overexpression of MCMs with the clinicopathological factors and progression in various types of cancers has been confirmed in several studies (9)(10)(11)(12)(13)(14)(15). However, there are few studies that have investigated the expression levels of MCM5 and their relationship with the clinicopathological factors in tumours (13)(14)(15)(16)(17).…”

mentioning

confidence: 83%

MCM5 Expression Is Associated With the Grade of Malignancy and Ki-67 Antigen in LSCC

et al. 2019

View full text Add to dashboard Cite

Background/Aim: The minichromosome maintenance proteins (MCMs) may be potential biomarkers of cancer cell proliferation. They are essential to initiate DNA replication. The aim of the study was to investigate the level of MCM5 expression in benign lesions (BLs) and laryngeal squamous cell cancer (LSCC). Materials and Methods: Immunohistochemical (IHC) analysis was carried out on 83 LSCCs and 10 BLs. Western-blot, immunofluorescence analysis (IF) and real-time PCR (RT-PCR) were performed using HEp-2 cancer cells and HaCaT keratinocytes. Results: The expression of MCM5 was higher in LSCC than in the BLs (p<0.0001) and was higher in subsequent malignancies of LSCC. Positive correlations were demonstrated between the expression levels of MCM5 and the Ki-67 antigen. In vitro studies have confirmed that the expression of MCM5 is elevated in cancer cells. Conclusion: MCM5 protein may be used as a potential marker of cancer cell proliferation in LSCC.

show abstract

MicroRNA-10b and minichromosome maintenance complex component 5 gene as prognostic biomarkers in breast cancer

Cited by 32 publications

References 25 publications

miR-10b is a prognostic marker in clear cell renal cell carcinoma

miR-10b is a prognostic marker in clear cell renal cell carcinoma

Clinical Value of miR-101-3p and Biological Analysis of its Prospective Targets in Breast Cancer: A Study Based on The Cancer Genome Atlas (TCGA) and Bioinformatics

MCM5 Expression Is Associated With the Grade of Malignancy and Ki-67 Antigen in LSCC

Contact Info

Product

Resources

About